Jigar has spent nearly 20 years in the biotechnology industry in a variety of business functions. As CEO of Constellation Pharmaceuticals, Jigar leads a company focused on harnessing its deep scientific expertise in cancer epigenetics to advance two ongoing clinical programs.
Jigar rejoined Constellation in 2017 from Jounce Therapeutics, where was chief business officer. As the first employee at Jounce, he helped build the company from its inception to a 100-person, publicly traded R&D organization.
Before Jounce, Jigar had an earlier tenure at Constellation, serving as head of corporate development, leading business development, strategy, and program and alliance management functions.
Earlier, Jigar worked with Red Abbey Venture Partners, initially as a Kauffman Fellow, later as a principal and finally a venture partner. Earlier in his career, he held roles at Biogen and A.T. Kearney.
Education, Personal, and Fellowship
Jigar holds an M.B.A. from Columbia Business School and a B.A. in molecular biology and biochemistry and economics from Rutgers University.
Jigar is a member of KFP Class 10, and served his fellowship at Red Abbey under the mentorship of Matt Zuga.